Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Jan 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-01-25

Reporting Person: Grossi Federico (CHIEF MEDICAL OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-25	Common Stock	M	3500	$3.20	Acquired	39327	Direct
2021-01-25	Common Stock	M	11500	$3.76	Acquired	50827	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-25	Stock Option (Right to Buy)	$3.20	M	3500	Disposed	2024-12-12	Common Stock (3500)	Direct
2021-01-25	Stock Option (Right to Buy)	$3.76	M	11500	Disposed	2026-02-06	Common Stock (11500)	Direct

Footnotes

F1: This is a scheduled exercise form 10B5-1 trading plan.

F2: This option was granted on December 12, 2014 and is fully vested.

F3: This option was granted on February 8, 2016 and has vested as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.